72
Participants
Start Date
October 31, 2005
Primary Completion Date
April 30, 2008
Study Completion Date
April 30, 2008
MVA Smallpox Vaccine
MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 intramuscularly (IM).
MVA Smallpox Vaccine
MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^7 or 10\^8 TCID50 subcutaneously (SC).
Placebo
Sterile saline (0.9%) volume of 0.5 ml intradermally in the deltoid.
Placebo
Sterile saline (0.9%) volume of 0.5 ml subcutaneously in the deltoid.
MVA Smallpox Vaccine
MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10\^6 or 10\^7 TCID50 intradermally (ID).
Live vaccinia virus vaccine
Dryvax® smallpox vaccine administered at approximately day 180, dosage 10\^8 pfu/ml.
Placebo
Sterile saline (0.9%) volume of 0.5 ml intramuscularly in the deltoid.
Brigham and Women's Hospital - Infectious Diseases, Boston
National Institute of Allergy and Infectious Diseases (NIAID)
NIH